© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Latest Conference Articles
Efficacy and Safety of Fremanezumab Further Displayed: Stephanie Nahas-Geiger, MD
April 19th 2021, 2:00pm
American Academy of Neurology Annual Meeting
The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.
Implementing Patient-Specific Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN
April 18th 2021, 8:00pm
American Academy of Neurology Annual Meeting
The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care.
Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption
April 18th 2021, 6:00pm
American Academy of Neurology Annual Meeting
Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.
Switch to Siponimod Safe, Tolerable With No Washout, Study Finds
April 18th 2021, 2:00pm
American Academy of Neurology Annual Meeting
Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.
Multiple Independent Current Control DBS Associated With Improved Outcomes in Parkinson Disease
April 18th 2021, 11:00am
American Academy of Neurology Annual Meeting
No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.
Simple Interventions Improve Compliance With Patient-Specific Stroke Discharge Instructions
April 17th 2021, 7:00pm
American Academy of Neurology Annual Meeting
Researchers from Ascension Saint Agnes improved compliance in their hospital in providing patient-specific, stroke-dedicated discharge instructions.
Disparities in Stroke Rehabilitation: Sana Somani, MD, MBBS
April 17th 2021, 5:00pm
American Academy of Neurology Annual Meeting
The vascular neurology fellow at the University of Maryland Medical Center discussed findings that African American women had the lowest functional performance in stroke rehabilitation.
Rimegepant Safe in Patients With Prior Triptan Failure
April 17th 2021, 2:00pm
American Academy of Neurology Annual Meeting
Serious adverse events occurred in 3.7% and 2.4% of subjects in the subgroups of patients with 1 and 2 or more triptan failures, respectively.
Role of Social Determinants in Epilepsy Treatment Delays: Joseph Sirven, MD
April 17th 2021, 2:00pm
American Academy of Neurology Annual Meeting
The professor of neurology at Mayo Clinic discussed the reasoning for the research he presented at AAN 2021 on social determinants and their impact on epilepsy treatment times.
Negative Impacts on Cognition Not Observed With Pimavanserin for Dementia-Related Psychosis
April 16th 2021, 9:00pm
American Academy of Neurology Annual Meeting
The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.